US6858409B1
(en)
|
1988-05-27 |
2005-02-22 |
Amgen Inc. |
Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
|
US5075222A
(en)
|
1988-05-27 |
1991-12-24 |
Synergen, Inc. |
Interleukin-1 inhibitors
|
US6159460A
(en)
*
|
1988-05-27 |
2000-12-12 |
Amgen Inc. |
Method for treating interleukin-1 mediated diseases
|
US5510418A
(en)
*
|
1988-11-21 |
1996-04-23 |
Collagen Corporation |
Glycosaminoglycan-synthetic polymer conjugates
|
US7264944B1
(en)
|
1989-04-21 |
2007-09-04 |
Amgen Inc. |
TNF receptors, TNF binding proteins and DNAs coding for them
|
US5166322A
(en)
*
|
1989-04-21 |
1992-11-24 |
Genetics Institute |
Cysteine added variants of interleukin-3 and chemical modifications thereof
|
DE59010941D1
(de)
*
|
1989-04-21 |
2005-03-24 |
Amgen Inc |
TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
|
IL95031A
(en)
*
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
A method of producing a recombinant human necrotic factor absorber
|
US6143866A
(en)
*
|
1989-07-18 |
2000-11-07 |
Amgen, Inc. |
Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
|
US6552170B1
(en)
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
CA2100329C
(fr)
*
|
1991-01-18 |
2009-09-29 |
David F. Carmichael |
Methodes de traitement des troubles medies par le facteur de necrose tumorale
|
CA2160154A1
(fr)
*
|
1993-04-07 |
1994-10-13 |
George N. Cox |
Methodes d'utilisation de proteines de fixation de facteur de croissance de type insuline
|
WO1995000162A1
(fr)
*
|
1993-06-21 |
1995-01-05 |
Enzon, Inc. |
Synthese de peptides conjuges modifies, sur des sites specifiques
|
US5446090A
(en)
*
|
1993-11-12 |
1995-08-29 |
Shearwater Polymers, Inc. |
Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
|
WO1995032003A1
(fr)
*
|
1994-05-24 |
1995-11-30 |
Amgen Boulder Inc. |
Facteurs de croissance proches de l'insuline modifies
|
IT1269989B
(it)
*
|
1994-09-21 |
1997-04-16 |
Dompe Spa |
Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria
|
AU3830895A
(en)
*
|
1994-10-07 |
1996-05-02 |
Amgen Boulder Inc. |
Dimeric il-4 inhibitors
|
US5824784A
(en)
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
FR2727117A1
(fr)
*
|
1994-11-18 |
1996-05-24 |
Geffard Michel |
Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
|
US5795966A
(en)
*
|
1995-02-22 |
1998-08-18 |
Immunex Corp |
Antagonists of interleukin-15
|
WO1996035451A1
(fr)
*
|
1995-05-10 |
1996-11-14 |
Kyowa Hakko Kogyo Co., Ltd. |
Nouveau complexe de toxines
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
NZ503548A
(en)
|
1996-02-09 |
2001-09-28 |
Amgen Inc |
A fusion protein comprising an IL-1ra receptor antagonist with a constant domain of human immunoglobulin at the carboxy terminus
|
US5747639A
(en)
*
|
1996-03-06 |
1998-05-05 |
Amgen Boulder Inc. |
Use of hydrophobic interaction chromatography to purify polyethylene glycols
|
US5741778A
(en)
*
|
1996-03-19 |
1998-04-21 |
Amgen Inc. |
Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
DE19636889A1
(de)
*
|
1996-09-11 |
1998-03-12 |
Felix Dr Kratz |
Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
|
EP2002846B1
(fr)
|
1996-12-06 |
2017-01-25 |
Amgen Inc. |
Thérapie combinée utilisant un inhibiteur IL-1 pour traiter les maladies liées au IL-1
|
DE69724451T2
(de)
|
1996-12-06 |
2004-03-18 |
Amgen Inc., Thousand Oaks |
Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
|
US6294170B1
(en)
|
1997-08-08 |
2001-09-25 |
Amgen Inc. |
Composition and method for treating inflammatory diseases
|
IS4518A
(is)
*
|
1997-07-09 |
1999-01-10 |
Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group |
Nýtt lyfjaform fyrir bóluefni
|
US6013253A
(en)
*
|
1997-08-15 |
2000-01-11 |
Amgen, Inc. |
Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
|
EP1019515A1
(fr)
*
|
1997-10-01 |
2000-07-19 |
G.D. SEARLE & CO. |
Proteines de fusion comprenant une fraction d'angiostatine et leur utilisation dans un traitement anti-tumeur
|
CA2310575A1
(fr)
*
|
1997-11-07 |
1999-05-20 |
Uab Research Foundation |
Procede d'augmentation de l'expression genique
|
US6451986B1
(en)
*
|
1998-06-22 |
2002-09-17 |
Immunex Corporation |
Site specific protein modification
|
EP2158923B1
(fr)
|
1998-08-06 |
2013-02-27 |
Mountain View Pharmaceuticals, Inc. |
Conjugués peg-urate oxydase et utilisation associée
|
US6783965B1
(en)
|
2000-02-10 |
2004-08-31 |
Mountain View Pharmaceuticals, Inc. |
Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
|
PL200586B1
(pl)
|
1998-10-16 |
2009-01-30 |
Biogen Idec Inc |
Polipeptydy zawierające mutanty interferonu-beta-1a, kodujące je cząsteczki kwasów nukleinowych, komórki gospodarza transformowane tymi cząsteczkami, sposób wytwarzania polipeptydów, zawierające je kompozycje farmaceutyczne i zastosowania polipeptydów
|
AU762616B2
(en)
|
1998-10-16 |
2003-07-03 |
Biogen Ma Inc. |
Polymer conjugates of interferon beta-1a and uses
|
MEP42108A
(en)
|
1998-10-23 |
2011-02-10 |
Kiren Amgen Inc |
Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
|
DE60022336T2
(de)
|
1999-04-02 |
2006-06-22 |
Ajinomoto Co., Inc. |
Vefahren zur herstellung von peptiduntereinheiten aus polymer-proteinen
|
US20040220103A1
(en)
|
1999-04-19 |
2004-11-04 |
Immunex Corporation |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
US8106098B2
(en)
|
1999-08-09 |
2012-01-31 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
US6808902B1
(en)
|
1999-11-12 |
2004-10-26 |
Amgen Inc. |
Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
|
WO2001062827A2
(fr)
|
2000-02-22 |
2001-08-30 |
Shearwater Corporation |
Derives de polymere n-maleimidyle
|
EP2241328A1
(fr)
|
2000-05-12 |
2010-10-20 |
Immunex Corporation |
Inhibiteurs d'interleukine 1 dans le traitement de maladies
|
AU2001278416A1
(en)
*
|
2000-07-13 |
2002-01-30 |
Natimmune A/S |
Mannan-binding lectin (mbl) treatment of infections in individuals treated with tnf-alphainhibitors
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
CA2868614A1
(fr)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methodes pour administrer des anticorps anti-tnf.alpha.
|
CA2451955C
(fr)
|
2001-06-26 |
2015-09-29 |
Abgenix, Inc. |
Anticorps opgl
|
KR100453877B1
(ko)
|
2001-07-26 |
2004-10-20 |
메덱스젠 주식회사 |
연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
|
JP4123856B2
(ja)
|
2001-07-31 |
2008-07-23 |
日油株式会社 |
生体関連物質の修飾剤およびポリオキシアルキレン誘導体の製造方法
|
GB0125093D0
(en)
*
|
2001-10-18 |
2001-12-12 |
Univ Southampton |
Multimeric proteins
|
JP2007528691A
(ja)
|
2001-11-14 |
2007-10-18 |
セントカー・インコーポレーテツド |
抗il−6抗体、組成物、方法および使用
|
US20030149246A1
(en)
*
|
2002-02-01 |
2003-08-07 |
Russell John C. |
Macromolecular conjugates and processes for preparing the same
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
EP1927858B1
(fr)
|
2002-04-29 |
2013-01-09 |
Euro-Celtique S.A. |
Peptides à conformations contraintes se liant au récepteur ORL-1
|
US20040002451A1
(en)
|
2002-06-20 |
2004-01-01 |
Bruce Kerwin |
Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
|
AU2003280130B2
(en)
|
2002-06-28 |
2009-06-11 |
Centocor, Inc. |
Mammalian CH1 deleted mimetibodies, compositions, methods and uses
|
US9028822B2
(en)
|
2002-06-28 |
2015-05-12 |
Domantis Limited |
Antagonists against TNFR1 and methods of use therefor
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
DK2213685T3
(en)
|
2002-09-06 |
2014-03-03 |
Medarex Llc |
Therapeutic anti-IL-1R1 monoclonal antibody
|
WO2004024889A2
(fr)
*
|
2002-09-16 |
2004-03-25 |
Elusys Therapeutics, Inc. |
Production de molecules bispecifiques au moyen de lieurs de polyethylene glycol
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
US7432331B2
(en)
|
2002-12-31 |
2008-10-07 |
Nektar Therapeutics Al, Corporation |
Hydrolytically stable maleimide-terminated polymers
|
KR101025143B1
(ko)
|
2002-12-31 |
2011-04-01 |
넥타르 테라퓨틱스 |
가수분해상으로 안정한 말레이미드-종결 중합체
|
AU2003300139B2
(en)
|
2002-12-31 |
2008-08-28 |
Nektar Therapeutics |
Maleamic acid polymer derivatives and their bioconjugates
|
US20050176108A1
(en)
*
|
2003-03-13 |
2005-08-11 |
Young-Min Kim |
Physiologically active polypeptide conjugate having prolonged in vivo half-life
|
KR101163683B1
(ko)
|
2003-05-12 |
2012-07-10 |
아피맥스, 인크. |
에리스로포이에틴 수용체에 결합하는 신규의 펩티드
|
US7919118B2
(en)
|
2003-05-12 |
2011-04-05 |
Affymax, Inc. |
Spacer moiety for poly (ethylene glycol) modified peptide based compounds
|
MXPA05012313A
(es)
|
2003-05-12 |
2006-04-18 |
Affymax Inc |
Peptidos que se unen al receptor de eritropoyetina.
|
DE602004028725D1
(de)
*
|
2003-05-12 |
2010-09-30 |
Affymax Inc |
Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
EP1491554A1
(fr)
*
|
2003-06-23 |
2004-12-29 |
CONARIS research institute AG |
Solubles gp130-dimeres modifiée avec du PEG pour utilisation comme medicament
|
US7482376B2
(en)
|
2003-07-03 |
2009-01-27 |
3-Dimensional Pharmaceuticals, Inc. |
Conjugated complement cascade inhibitors
|
GB0316294D0
(en)
|
2003-07-11 |
2003-08-13 |
Polytherics Ltd |
Conjugated biological molecules and their preparation
|
UA89481C2
(uk)
|
2003-09-30 |
2010-02-10 |
Центокор, Инк. |
Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
|
AU2004287431B2
(en)
|
2003-10-27 |
2010-03-11 |
Amgen Inc. |
Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
|
BRPI0406605B8
(pt)
|
2003-11-13 |
2021-05-25 |
Hanmi Holdings Co Ltd |
conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
|
WO2005056636A2
(fr)
|
2003-12-03 |
2005-06-23 |
Nektar Therapeutics Al, Corporation |
Procede de preparation de polymeres fonctionnalises par maleimide
|
IL159670A0
(en)
*
|
2003-12-31 |
2004-06-01 |
Yeda Res & Dev |
Use of il-18 binding protein in inflammations
|
US7674464B2
(en)
*
|
2004-03-04 |
2010-03-09 |
The University Of Tennessee Research Foundation |
Intracellular interleukin-1 receptor antagonists
|
TW201705980A
(zh)
|
2004-04-09 |
2017-02-16 |
艾伯維生物技術有限責任公司 |
用於治療TNFα相關失調症之多重可變劑量療法
|
EP1773400A2
(fr)
|
2004-07-08 |
2007-04-18 |
Amgen Inc. |
Peptides therapeutiques
|
WO2006012451A2
(fr)
|
2004-07-22 |
2006-02-02 |
Five Prime Therapeutics, Inc. |
Compositions et procedes d'utilisation pour le facteur de stimulation de colonies de monocytes, de granulocytes et de cellules dendritiques dans le traitement de maladies
|
US7393662B2
(en)
|
2004-09-03 |
2008-07-01 |
Centocor, Inc. |
Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
|
AU2005296277A1
(en)
*
|
2004-10-12 |
2006-04-27 |
Amprotein Corporation |
Chimeric protein
|
WO2006081190A2
(fr)
|
2005-01-25 |
2006-08-03 |
Five Prime Therapeutics, Inc. |
Compositions et methodes de traitement de troubles cardiaques
|
US7402730B1
(en)
|
2005-02-03 |
2008-07-22 |
Lexicon Pharmaceuticals, Inc. |
Knockout animals manifesting hyperlipidemia
|
CN100381420C
(zh)
*
|
2005-03-23 |
2008-04-16 |
于勇海 |
一种n-乙酰基半胱氨酸衍生物与应用
|
KR100754667B1
(ko)
|
2005-04-08 |
2007-09-03 |
한미약품 주식회사 |
비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물
|
PL3321359T3
(pl)
|
2005-04-11 |
2021-06-28 |
Horizon Pharma Rheumatology Llc |
Wariantowe postacie oksydazy moczanowej i ich zastosowanie
|
US7833979B2
(en)
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
PE20061324A1
(es)
|
2005-04-29 |
2007-01-15 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, metodos y usos
|
CN101500607B
(zh)
|
2005-05-16 |
2013-11-27 |
阿布维生物技术有限公司 |
TNFα抑制剂治疗腐蚀性多关节炎的用途
|
US8324159B2
(en)
|
2005-06-03 |
2012-12-04 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US7550433B2
(en)
|
2005-06-03 |
2009-06-23 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
TR201902033T4
(tr)
|
2005-06-30 |
2019-03-21 |
Janssen Biotech Inc |
Anti-IL-23 antikorları, bileşimleri, yöntemleri ve kullanımları.
|
WO2007014123A2
(fr)
|
2005-07-22 |
2007-02-01 |
Five Prime Therapeutics, Inc. |
Compositions et procedes de traitement de maladies a l'aide de proteines de fusion fgfr
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
US8168592B2
(en)
|
2005-10-21 |
2012-05-01 |
Amgen Inc. |
CGRP peptide antagonists and conjugates
|
PE20070684A1
(es)
|
2005-11-14 |
2007-08-06 |
Amgen Inc |
MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
|
MX2008008621A
(es)
|
2005-12-29 |
2008-11-27 |
Centocor Inc |
Anticuerpos anti-il-23 humanos, composiciones, metodos y usos.
|
TW200745163A
(en)
|
2006-02-17 |
2007-12-16 |
Syntonix Pharmaceuticals Inc |
Peptides that block the binding of IgG to FcRn
|
ZA200807028B
(en)
*
|
2006-02-23 |
2009-11-25 |
Fibrex Medical Res & Dev Gmbh |
Peptides and peptide derivatives as well as pharmaceutical compositions containing the same
|
WO2007112005A2
(fr)
|
2006-03-24 |
2007-10-04 |
Syntonix Pharmaceuticals, Inc. |
Protéine pc5 utilisée comme enzyme de traitement du propeptide du facteur ix
|
SG170837A1
(en)
|
2006-04-05 |
2011-05-30 |
Abbott Biotech Ltd |
Antibody purification
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
US9283260B2
(en)
|
2006-04-21 |
2016-03-15 |
Amgen Inc. |
Lyophilized therapeutic peptibody formulations
|
US8377448B2
(en)
|
2006-05-15 |
2013-02-19 |
The Board Of Trustees Of The Leland Standford Junior University |
CD47 related compositions and methods for treating immunological diseases and disorders
|
US20100150834A1
(en)
*
|
2006-09-15 |
2010-06-17 |
The Burnham Institute |
High affinity ephb receptor binding compounds and methods of use thereof
|
US7833527B2
(en)
|
2006-10-02 |
2010-11-16 |
Amgen Inc. |
Methods of treating psoriasis using IL-17 Receptor A antibodies
|
AR063384A1
(es)
|
2006-10-25 |
2009-01-28 |
Amgen Inc |
Agentes terapeuticos a base de peptidos derivados de toxinas
|
CA2672049C
(fr)
|
2006-12-08 |
2016-05-10 |
Lexicon Pharmaceuticals, Inc. |
Anticorps monoclonaux diriges contre angptl3
|
UY30820A1
(es)
|
2006-12-21 |
2008-07-03 |
Centocor Inc |
Uso de agonistas del receptor de glp-1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
|
CN101678082B
(zh)
|
2007-03-26 |
2013-06-19 |
再生医药有限公司 |
使用cxcl9和抗cxcl9抗体促进骨髓保护和再生的方法
|
GB0708376D0
(en)
|
2007-05-01 |
2007-06-06 |
Alligator Bioscience Ab |
Novel polypeptides and uses thereof
|
AU2008262490B2
(en)
|
2007-05-22 |
2011-11-17 |
Amgen Inc. |
Compositions and methods for producing bioactive fusion proteins
|
US8906844B2
(en)
|
2007-08-09 |
2014-12-09 |
Biogen Idec Hemophilia Inc. |
Immunomodulatory peptides
|
US8323635B2
(en)
|
2007-11-14 |
2012-12-04 |
General Regeneratives, Ltd. |
Methods of using interleukin-1 receptor antagonist as a myeloprotective agent
|
AR072596A1
(es)
|
2008-07-23 |
2010-09-08 |
Hanmi Pharmaceutical Co Ltd |
Un complejo proteico que comprende una proteina dimerica y un polimero no peptidico
|
NZ590816A
(en)
|
2008-08-14 |
2013-02-22 |
Cephalon Australia Pty Ltd |
Anti-il-12/il-23 antibodies
|
US8088890B2
(en)
|
2008-09-26 |
2012-01-03 |
Fibrex Medical Research & Development Gmbh |
Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
|
PL2356269T3
(pl)
|
2008-10-31 |
2016-12-30 |
|
Kompozycje białek rusztowania oparte na domenie fibronektyny typu III, sposoby i zastosowania
|
CA2742710A1
(fr)
*
|
2008-11-04 |
2010-05-14 |
Janssen Pharmaceutica Nv |
Agonistes peptidiques du recepteur d'hormone de liberation de la corticotropine de type 2 (crhr2) et leurs utilisations
|
GB0823309D0
(en)
|
2008-12-19 |
2009-01-28 |
Univ Bath |
Functionalising reagents and their uses
|
CN102325823B
(zh)
*
|
2008-12-22 |
2014-02-26 |
通用电气健康护理有限公司 |
得到改性聚乙二醇中间体的合成
|
US8716448B2
(en)
|
2009-02-03 |
2014-05-06 |
Amunix Operating Inc. |
Coagulation factor VII compositions and methods of making and using same
|
CN102596992B
(zh)
|
2009-02-12 |
2015-09-09 |
詹森生物科技公司 |
基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
|
KR101861547B1
(ko)
|
2009-06-25 |
2018-07-02 |
크레알타 파마슈티칼스 엘엘씨 |
페길화된 유리카아제 치료 중에 혈청 요산을 모니터링하여 주입 반응의 위험성 및 반응의 항체매개 상실을 예측하는 방법 및 키트
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
CN101690801B
(zh)
|
2009-10-26 |
2012-08-01 |
上海交通大学 |
白细胞介素-1受体拮抗剂的用途及其药物组合物
|
MY182680A
(en)
|
2010-01-15 |
2021-01-29 |
Amgen K A Inc |
Antibody formulation and therapeutic regimens
|
EA031203B1
(ru)
|
2010-03-30 |
2018-11-30 |
Янссен Байотек Инк. |
Гуманизированные антитела к il-25
|
GB201105584D0
(en)
|
2011-04-01 |
2011-05-18 |
Imp Innovations Ltd |
Cancer methods
|
KR101834026B1
(ko)
|
2010-06-19 |
2018-03-02 |
메모리얼 슬로안-케터링 캔서 센터 |
항-gd2 항체
|
EP2585098B1
(fr)
|
2010-06-28 |
2014-08-27 |
Five Prime Therapeutics, Inc. |
Domaines extracellulaires fzd8 et molécules de fusion au domaine extracellulaire fzd8 pour l'utilisation dans le traitement de l'obésité et troubles liés à l'obésité
|
EP3508573A1
(fr)
|
2010-07-09 |
2019-07-10 |
Bioverativ Therapeutics Inc. |
Systèmes de traitement de facteur viii et procédés associés
|
AU2011329127B2
(en)
|
2010-11-15 |
2015-09-03 |
Five Prime Therapeutics, Inc. |
FGFR1 extracellular domain combination therapies
|
JP6033229B2
(ja)
|
2010-11-24 |
2016-11-30 |
レクシコン ファーマシューティカルズ インコーポレイテッド |
Notumペクチンアセチルエステラーゼと結合する抗体
|
WO2012097238A2
(fr)
|
2011-01-14 |
2012-07-19 |
Five Prime Therapeutics, Inc. |
Antagonistes de l'il-27 utilisables en vue du traitement de maladies inflammatoires
|
EP2686340A2
(fr)
|
2011-03-16 |
2014-01-22 |
Amgen Inc. |
Inhibiteurs puissants et sélectifs de nav1.3 et nav1.7
|
WO2012149197A2
(fr)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
|
MY180714A
(en)
|
2011-07-08 |
2020-12-07 |
Bioverativ Therapeutics Inc |
Factor viii chimeric and hybrid polypeptides, and methods of use thereof
|
CA2841185C
(fr)
|
2011-07-22 |
2021-05-25 |
Csl Behring Gmbh |
Anticorps monoclonaux inhibiteurs anti-facteur xii/xiia et leurs utilisations
|
US20140234330A1
(en)
|
2011-07-22 |
2014-08-21 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
EP2785364B1
(fr)
|
2011-11-29 |
2019-01-09 |
Proclara Biosciences, Inc. |
Utilisation de p3 de bactériophages en tant qu'agents de liaison aux amyloïdes
|
EP2623110A1
(fr)
|
2012-01-31 |
2013-08-07 |
CSL Behring GmbH |
Inhibiteurs de facteur XII pour le traitement de troubles inflammatoires neurologiques
|
KR20190094480A
(ko)
|
2012-02-15 |
2019-08-13 |
바이오버라티브 테라퓨틱스 인크. |
재조합 인자 viii 단백질
|
CN111548418A
(zh)
|
2012-02-15 |
2020-08-18 |
比奥贝拉蒂治疗公司 |
因子viii组合物及其制备和使用方法
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US9334319B2
(en)
|
2012-04-20 |
2016-05-10 |
Abbvie Inc. |
Low acidic species compositions
|
WO2013158273A1
(fr)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Procédés de modulation de la distribution de variant de lysine c-terminal
|
DK2847231T3
(da)
|
2012-05-10 |
2019-10-14 |
Bioatla Llc |
Multispecifikke monoklonale antistoffer
|
MX349035B
(es)
|
2012-05-17 |
2017-07-07 |
Extend Biosciences Inc |
Portadores para el suministro mejorado de farmaco.
|
WO2013170636A1
(fr)
|
2012-05-18 |
2013-11-21 |
爱德迪安(北京)生物技术有限公司 |
Protéine et conjugué protéique pour le traitement du diabète et applications associées
|
EP3404105A1
(fr)
|
2012-07-06 |
2018-11-21 |
Bioverativ Therapeutics Inc. |
Lignée cellulaire exprimant des polypeptides du facteur viii à chaîne unique et ses utilisations
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
PT2906235T
(pt)
|
2012-10-02 |
2017-09-28 |
Proclara Biosciences Inc |
Utilização de p3 de proteínas de fusão de bacteriófago como agentes ligantes amilóides
|
AU2013331000B2
(en)
|
2012-10-18 |
2018-04-19 |
Bioverativ Therapeutics Inc. |
Methods of using a fixed dose of a clotting factor
|
WO2014070953A1
(fr)
|
2012-10-30 |
2014-05-08 |
Biogen Idec Ma Inc. |
Procédés d'utilisation du polypeptide fviii
|
US9383357B2
(en)
|
2012-12-07 |
2016-07-05 |
Northwestern University |
Biomarker for replicative senescence
|
JP6426107B2
(ja)
|
2012-12-20 |
2018-11-21 |
アムジエン・インコーポレーテツド |
Apj受容体アゴニストおよびその使用
|
JP6636334B2
(ja)
|
2013-03-08 |
2020-01-29 |
ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー |
遠隔虚血再灌流傷害の治療および予防
|
SG11201507230PA
(en)
|
2013-03-12 |
2015-10-29 |
Abbvie Inc |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
TW201446792A
(zh)
|
2013-03-12 |
2014-12-16 |
Amgen Inc |
Nav1.7之強效及選擇性抑制劑
|
WO2014151878A2
(fr)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
EP2968545B1
(fr)
|
2013-03-15 |
2019-03-06 |
Memorial Sloan Kettering Cancer Center |
Anticorps anti-gd2 à haute affinité
|
AU2014228938B2
(en)
|
2013-03-15 |
2019-05-02 |
Bioverativ Therapeutics Inc. |
Factor IX polypeptide formulations
|
HUE047933T2
(hu)
|
2013-03-15 |
2020-05-28 |
Bioverativ Therapeutics Inc |
Faktor VIII polipeptid készítmények
|
US20160067307A1
(en)
|
2013-05-01 |
2016-03-10 |
Five Prime Therapeutics, Inc. |
Methods of treating cancer
|
AU2014268519A1
(en)
|
2013-05-23 |
2015-11-05 |
Five Prime Therapeutics, Inc. |
Methods of treating cancer
|
US9988444B2
(en)
|
2013-05-28 |
2018-06-05 |
Proclara Biosciences, Inc. |
Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
|
ES2897746T3
(es)
|
2013-06-28 |
2022-03-02 |
Csl Behring Gmbh |
Terapia combinada con un inhibidor del Factor XII y un inhibidor de C1
|
EP4108254A1
(fr)
|
2013-08-14 |
2022-12-28 |
Bioverativ Therapeutics Inc. |
Protéines de facteur viii de recombinaison
|
TW202003554A
(zh)
|
2013-08-14 |
2020-01-16 |
美商百歐維拉提夫治療公司 |
因子viii-xten融合物及其用途
|
US9598667B2
(en)
|
2013-10-04 |
2017-03-21 |
Abbvie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
WO2015067791A1
(fr)
|
2013-11-11 |
2015-05-14 |
Ascendis Pharma Relaxin Division A/S |
Promédicaments à bae de relaxine
|
WO2015073884A2
(fr)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Compositions de protéines de liaison génétiquement glycomodifiées
|
EP4332839A2
(fr)
|
2013-12-06 |
2024-03-06 |
Bioverativ Therapeutics Inc. |
Outils pharmacocinétiques de population et leurs utilisations
|
MX2016012447A
(es)
|
2014-03-24 |
2017-01-06 |
Biogen Ma Inc |
Formulaciones de factor ix liofilizadas.
|
US20170174772A1
(en)
|
2014-03-31 |
2017-06-22 |
Kirin-Amgen, Inc. |
Methods of treating nail and scalp psoriasis
|
GB201406767D0
(en)
|
2014-04-15 |
2014-05-28 |
Cancer Rec Tech Ltd |
Humanized anti-Tn-MUC1 antibodies anf their conjugates
|
US20160000936A1
(en)
|
2014-06-10 |
2016-01-07 |
Abbvie Inc. |
Biomarkers for inflammatory disease and methods of using same
|
EP4257152A3
(fr)
|
2014-06-10 |
2023-12-06 |
Amgen Inc. |
Polypeptides d'apéline
|
PL3157548T3
(pl)
|
2014-06-18 |
2022-01-17 |
Csl Behring Gmbh |
Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym
|
MX2017004148A
(es)
|
2014-09-29 |
2017-07-07 |
Hutchinson Fred Cancer Res |
Composiciones, kits y metodos para inducir citorresistencia adquirida usando inductores de proteinas de estres.
|
US9585934B2
(en)
|
2014-10-22 |
2017-03-07 |
Extend Biosciences, Inc. |
Therapeutic vitamin D conjugates
|
US9789197B2
(en)
|
2014-10-22 |
2017-10-17 |
Extend Biosciences, Inc. |
RNAi vitamin D conjugates
|
WO2016065052A1
(fr)
|
2014-10-22 |
2016-04-28 |
Extend Biosciences, Inc. |
Conjugués insuline vitamine d
|
MA40835A
(fr)
|
2014-10-23 |
2017-08-29 |
Biogen Ma Inc |
Anticorps anti-gpiib/iiia et leurs utilisations
|
GB201419108D0
(en)
|
2014-10-27 |
2014-12-10 |
Glythera Ltd |
Materials and methods relating to linkers for use in antibody drug conjugates
|
MA40861A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Anticorps anti-glycoprotéines iib/iiia
|
CN107250154A
(zh)
|
2014-12-03 |
2017-10-13 |
普罗克拉拉生物科学股份有限公司 |
包含缺乏糖基化信号的经修饰的噬菌体g3p氨基酸序列的多肽
|
AU2016233309B2
(en)
|
2015-03-17 |
2021-11-18 |
Memorial Sloan Kettering Cancer Center |
Anti-MUC16 antibodies and uses thereof
|
WO2016160976A2
(fr)
|
2015-03-30 |
2016-10-06 |
Abbvie Inc. |
Protéines de liaison au tnf monovalentes
|
EP3078675A1
(fr)
|
2015-04-10 |
2016-10-12 |
Ares Trading S.A. |
Régime de dosage à induction pour le traitement des maladies liées au tnf alpha
|
GB201506389D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
JP6909203B2
(ja)
|
2015-08-03 |
2021-07-28 |
バイオベラティブ セラピューティクス インコーポレイテッド |
第ix因子融合タンパク質及びそれらの製造方法及び使用方法
|
US20170157215A1
(en)
|
2015-12-04 |
2017-06-08 |
Jomoco, Corp. |
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
|
EP3436477A2
(fr)
|
2016-03-29 |
2019-02-06 |
Janssen Biotech, Inc. |
Methode de traitement du psoriasis avec dosage intervalle augmenté d'anticorps anti-il12 et/ou -23
|
MA45473A
(fr)
|
2016-04-04 |
2019-02-13 |
Shire Human Genetic Therapies |
Inhibiteur de c1 estérase conjugué et ses utilisations
|
WO2017173494A1
(fr)
|
2016-04-06 |
2017-10-12 |
Csl Limited |
Méthode de traitement de l'athérosclérose
|
CA3021271A1
(fr)
|
2016-04-25 |
2017-11-02 |
Glaxosmithkline Intellectual Property Development Limited |
Nope pour le traitement de la perte et de la faiblesse musculaire pathologique
|
TWI759301B
(zh)
|
2016-05-24 |
2022-04-01 |
美商安美基公司 |
聚乙二醇化卡非佐米化合物
|
CA3030841A1
(fr)
|
2016-07-14 |
2018-01-18 |
Fred Hutchinson Cancer Research Center |
Constructions multiples de domaines de liaison bi-specifiques ayant une liaison a l'epitope differente pour traiter le cancer
|
JP2019524721A
(ja)
|
2016-07-15 |
2019-09-05 |
ポセイダ セラピューティクス, インコーポレイテッド |
キメラ抗原受容体および使用方法
|
MX2019000641A
(es)
|
2016-07-15 |
2019-06-10 |
Poseida Therapeutics Inc |
Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso.
|
US10041044B2
(en)
|
2016-07-29 |
2018-08-07 |
Trustees Of Boston University |
Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
|
EP3519049A4
(fr)
|
2016-09-30 |
2020-05-27 |
Janssen Biotech, Inc. |
Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique contre l'il-23
|
WO2018093841A1
(fr)
|
2016-11-16 |
2018-05-24 |
Janssen Biotech, Inc. |
Procédé de traitement du psoriasis avec un anticorps anti-il-23 spécifique
|
CA3044838A1
(fr)
|
2016-12-02 |
2018-06-07 |
Bioverativ Therapeutics Inc. |
Procedes d'induction de tolerance immunitaire a des facteurs de coagulation
|
IL266972B2
(en)
|
2016-12-02 |
2024-04-01 |
Bioverativ Therapeutics Inc |
Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
|
JOP20190162A1
(ar)
|
2016-12-30 |
2019-06-27 |
Biocad Joint Stock Co |
تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
|
EP3574012A1
(fr)
|
2017-01-27 |
2019-12-04 |
Memorial Sloan Kettering Cancer Center |
Molécules bispécifiques de liaison à her2 et cd3
|
CN110234351A
(zh)
|
2017-01-30 |
2019-09-13 |
詹森生物科技公司 |
用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
|
TW201831521A
(zh)
|
2017-01-31 |
2018-09-01 |
美商生物化學醫療公司 |
因子ix融合蛋白以及其製備方法及使用方法
|
CN110418652A
(zh)
|
2017-02-07 |
2019-11-05 |
詹森生物科技公司 |
用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法
|
AU2018235756A1
(en)
|
2017-03-13 |
2019-10-10 |
Poseida Therapeutics, Inc. |
Compositions and methods for selective elimination and replacement of hematopoietic stem cells
|
CN110536703A
(zh)
|
2017-04-20 |
2019-12-03 |
Adc治疗有限公司 |
使用抗axl抗体-药物缀合物的组合疗法
|
WO2018209125A1
(fr)
|
2017-05-10 |
2018-11-15 |
Fred Hutchinson Cancer Research Center |
Anticorps contre le virus d'epstein-barr, vaccins et leurs utilisations
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
KR20200116917A
(ko)
|
2017-12-20 |
2020-10-13 |
포세이다 테라퓨틱스, 인크. |
Vcar 조성물 및 사용 방법
|
WO2019150309A1
(fr)
|
2018-02-02 |
2019-08-08 |
Hammack Scott |
Modulateurs de gpr68 et leurs utilisations pour le traitement et la prévention de maladies
|
KR20200129125A
(ko)
|
2018-03-05 |
2020-11-17 |
얀센 바이오테크 인코포레이티드 |
항-il23 특이적 항체로 크론병을 치료하는 방법
|
TW202017592A
(zh)
|
2018-03-07 |
2020-05-16 |
美商波西達治療公司 |
CARTyrin組成物和使用方法
|
MA52590A
(fr)
|
2018-05-11 |
2021-03-17 |
Janssen Biotech Inc |
Méthodes de traitement de la dépression à l'aide d'anticorps il-23
|
US20210238238A1
(en)
|
2018-05-16 |
2021-08-05 |
Csl Limited |
Soluble complement receptor type i variants and uses thereof
|
WO2019222682A1
(fr)
|
2018-05-18 |
2019-11-21 |
Bioverativ Therapeutics Inc. |
Procédés de traitement de l'hémophilie a
|
JP2021530697A
(ja)
|
2018-07-18 |
2021-11-11 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il23特異的抗体で治療した後の持続応答予測因子
|
WO2020035482A1
(fr)
|
2018-08-13 |
2020-02-20 |
Iltoo Pharma |
Combinaison d'interleukine 2 et d'un inhibiteur de l'interleukine 1, conjugués et utilisations thérapeutiques de celle-ci
|
US20220098613A1
(en)
|
2018-09-12 |
2022-03-31 |
Fred Hutchinson Cancer Research Center |
Reducing cd33 expression to selectively protect therapeutic cells
|
KR20230148273A
(ko)
|
2018-09-24 |
2023-10-24 |
얀센 바이오테크 인코포레이티드 |
항-il12/il23 항체로 궤양성 결장염을 치료하는 안전하고 효과적인 방법
|
MA55149A
(fr)
|
2018-11-20 |
2021-09-29 |
Janssen Biotech Inc |
Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
|
US20200197517A1
(en)
|
2018-12-18 |
2020-06-25 |
Janssen Biotech, Inc. |
Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
|
WO2020132396A1
(fr)
|
2018-12-20 |
2020-06-25 |
Poseida Therapeutics, Inc. |
Compositions de nanotransposons et procédés d'utilisation
|
JP2022518208A
(ja)
|
2019-01-15 |
2022-03-14 |
ヤンセン バイオテツク,インコーポレーテツド |
若年性特発性関節炎の治療のための抗tnf抗体、組成物、及び方法
|
WO2020152544A1
(fr)
|
2019-01-23 |
2020-07-30 |
Janssen Biotech, Inc. |
Compositions d'anticorps anti-tnf destinées à être utilisées dans des méthodes de traitement d'arthrite psoriasique
|
KR20210142002A
(ko)
|
2019-03-14 |
2021-11-23 |
얀센 바이오테크 인코포레이티드 |
항-tnf 항체 조성물을 생성하기 위한 제조 방법
|
CA3133388A1
(fr)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Procedes de production de compositions d'anticorps anti-tnf
|
CN113825765A
(zh)
|
2019-03-14 |
2021-12-21 |
詹森生物科技公司 |
用于制备抗il12/il23抗体组合物的制造方法
|
MA55283A
(fr)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech Inc |
Procédés de production de compositions d'anticorps anti-tnf
|
EA202192459A1
(ru)
|
2019-03-18 |
2021-11-25 |
Янссен Байотек, Инк. |
Способ лечения псориаза антителом к il12/il23 у субъектов детского возраста
|
US11780911B2
(en)
|
2019-05-23 |
2023-10-10 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
|
CN113939531A
(zh)
|
2019-06-03 |
2022-01-14 |
詹森生物科技公司 |
用于治疗银屑病关节炎的抗tnf抗体组合物和方法
|
MX2021014882A
(es)
|
2019-06-03 |
2022-03-25 |
Janssen Biotech Inc |
Anticuerpos anti-tnf, composiciones y métodos para el tratamiento de la espondilitis anquilosante activa.
|
WO2021028752A1
(fr)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anticorps anti-tfn pour le traitement du diabète de type i
|
US20220372105A1
(en)
|
2019-09-05 |
2022-11-24 |
Poseida Therapeutics, Inc. |
Allogeneic cell compositions and methods of use
|
KR20220117915A
(ko)
|
2019-12-20 |
2022-08-24 |
포세이다 테라퓨틱스, 인크. |
항-muc1 조성물 및 사용 방법
|
EP4118107A1
(fr)
|
2020-03-11 |
2023-01-18 |
Poseida Therapeutics, Inc. |
Récepteurs stimulateurs chimériques et procédés d'utilisation dans l'activation et la différenciation de lymphocytes t
|
US20230190811A1
(en)
|
2020-04-14 |
2023-06-22 |
Poseida Therapeutics, Inc. |
Compositions and methods for use in the treatment of cancer
|
WO2021214588A1
(fr)
|
2020-04-21 |
2021-10-28 |
Janssen Biotech, Inc. |
Agent anti-tnf alpha pour traiter des infections à coronavirus
|
WO2021214587A1
(fr)
|
2020-04-21 |
2021-10-28 |
Janssen Biotech, Inc. |
Agent anti-tnf alpha pour traiter des infections virales
|
EP4231999A1
(fr)
|
2020-10-21 |
2023-08-30 |
Poseida Therapeutics, Inc. |
Compositions et procédés d'administration d'acides nucléiques
|
EP4297728A1
(fr)
|
2021-02-23 |
2024-01-03 |
Poseida Therapeutics, Inc. |
Compositions et procédés d'administration d'acides nucléiques
|
US20240060090A1
(en)
|
2021-02-23 |
2024-02-22 |
Poseida Therapeutics, Inc. |
Genetically modified induced pluripotent stem cells and methods of use thereof
|
AU2022306973A1
(en)
|
2021-07-09 |
2024-02-22 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-il12/il23 antibody compositions
|
CN117957251A
(zh)
|
2021-07-09 |
2024-04-30 |
詹森生物科技公司 |
用于制备抗tnf抗体组合物的制造方法
|
WO2023281462A1
(fr)
|
2021-07-09 |
2023-01-12 |
Janssen Biotech, Inc. |
Procédés de fabrication pour produire des compositions d'anticorps anti-tnf
|
WO2023060088A1
(fr)
|
2021-10-04 |
2023-04-13 |
Poseida Therapeutics, Inc. |
Compositions de transposons et leurs procédés d'utilisation
|
WO2023073615A1
(fr)
|
2021-10-29 |
2023-05-04 |
Janssen Biotech, Inc. |
Méthodes de traitement de la maladie de crohn avec un anticorps spécifique anti-il23
|
US20230151087A1
(en)
|
2021-11-15 |
2023-05-18 |
Janssen Biotech, Inc. |
Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
|
WO2023095000A1
(fr)
|
2021-11-23 |
2023-06-01 |
Janssen Biotech, Inc. |
Méthode de traitement de la rectocolite hémorragique avec un anticorps spécifique anti-il23
|
WO2023141576A1
(fr)
|
2022-01-21 |
2023-07-27 |
Poseida Therapeutics, Inc. |
Compositions et procédés d'administration d'acides nucléiques
|
WO2023164573A1
(fr)
|
2022-02-23 |
2023-08-31 |
Poseida Therapeutics, Inc. |
Cellules modifiées et leurs procédés d'utilisation
|
WO2023222565A1
(fr)
|
2022-05-16 |
2023-11-23 |
Institut National de la Santé et de la Recherche Médicale |
Procédés d'évaluation de l'épuisement de cellules souches hématopoïétiques induites par une inflammation chronique
|